{"id":44580,"date":"2020-09-01T16:13:34","date_gmt":"2020-09-01T16:13:34","guid":{"rendered":"https:\/\/www.rightsdirect.com\/resource-library\/%resource_type%\/mirati-therapeutics\/"},"modified":"2023-03-28T15:24:48","modified_gmt":"2023-03-28T15:24:48","slug":"mirati-therapeutics","status":"publish","type":"resource","link":"https:\/\/www.rightsdirect.com\/de\/resource-library\/fallstudien\/mirati-therapeutics\/","title":{"rendered":"How Mirati Therapeutics Launched RightFind Enterprise for Its At-Home Work Force"},"content":{"rendered":"
Mirati Therapeutics has an ever-present need for copyright complaint access to information. The content acquisition process prior to the Covid-19 pandemic was based on both departmental and individual preferences; there wasn’t a single, streamlined approach. This inconsistency created data silos internally and left users without a centralized place to access content and collaborate. Many researchers, out of habit or convenience, were storing content directly on their desktops or personal folders, so ease of sharing, or the ability to know what was already available under Mirati’s licenses, was hindered.<\/p>\n